Studieresultaterne viser, at 94% (277/ 296) af de kvalificerede patienter kom i enkeltstofbehandling med bevacizumab ved serie 7.
Study results show that 94% (277 / 296) of eligible patients went on to receive single agent bevacizumab at cycle 7.